查看購物車
  • Simplified Chinese
  • English
  • Japanese
2031年亞太地區青光眼治療市場預測 - 區域分析 - 按藥物類別、適應症和配銷通路
市場調查報告書
商品編碼
1764892

2031年亞太地區青光眼治療市場預測 - 區域分析 - 按藥物類別、適應症和配銷通路

Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 137 Pages | 訂單完成後即時交付

價格

2023 年亞太青光眼治療市場價值為 12.118 億美元，預計到 2031 年將達到 15.9841 億美元；預計 2023 年至 2031 年的複合年成長率為 3.5%。

穿戴式科技的發展推動亞太青光眼治療市場

技術創新一直是任何生命科學學科（包括眼科學）的基礎，因為現代設備是準確診斷和改進治療的關鍵。治療方法的進步使得青光眼的治療得到改善。穿戴式青光眼診斷和治療產品已成為潛在的解決方案。傳統診斷技術提供可靠的眼壓資料，而 Sensimed Triggerfish 等創新隱形眼鏡則提供持續的眼壓追蹤。先進的藥物洗脫隱形眼鏡也正在成為青光眼治療的潛在解決方案。 2023 年 3 月，SpyGlass Pharma 發布了其首次人體青光眼治療試驗的 6 個月資料。資料顯示，其新的藥物輸送平台（一種帶有藥物洗脫墊的一體式疏水性丙烯酸人工水晶體）繼續顯著降低患有青光眼或眼高壓患者的眼壓。因此，此類現代穿戴式產品的開發可能會在未來幾年推動對青光眼治療的需求。

亞太青光眼治療市場概況

亞太地區的青光眼治療市場細分為中國、日本、印度、澳洲、韓國和亞太其他地區。該地區市場的成長歸因於青光眼發病率的上升、老年人口的增加以及促進研究活動的投資激增。主要市場參與者正在採取合併、收購、產品發布和融資等策略來擴大其市場佔有率。 2023 年 2 月，兆科眼科的比馬前列素噻嗎洛爾滴眼液獲得國家藥品監督管理局 (NMPA) 的上市許可，用於治療青光眼。 2023 年 2 月，參天製藥股份有限公司的 STN1011101 滴眼液申請獲得了 NMPA 的上市許可。這款不含防腐劑的配方含有 0.0015% 的他氟前列素和 0.5% 的噻嗎洛爾，由參天製藥和 AGC Inc. 共同開發。該藥物旨在滿足中國青光眼治療中尚未滿足的需求。

2022年2月發表在《BMC眼科期刊》的研究報告顯示，中國是全球青光眼發生率最高的國家。此外，2020年，中國各類青光眼患者人數達1,558萬人，預計2050年將激增至2,516萬人。青光眼的高發生率預計將在未來推動該疾病治療藥物的成長。中國青光眼治療市場的成長主要歸功於市場參與者採取的各種成長策略以及人口老化的加劇。

亞太青光眼治療市場收入及預測（2031年）（百萬美元）

亞太青光眼治療市場區隔

亞太青光眼治療市場按藥物類別、適應症、配銷通路和國家分類。

依藥物類別，亞太地區青光眼治療市場細分為BETA受體阻斷劑、α腎上腺素激動劑、前列腺素類似物、碳酸酐酶抑制劑、複方藥物及其他。前列腺素類似物在2023年佔據了最大的市場。

依適應症分類，亞太地區青光眼治療市場分為開角型青光眼、閉角型青光眼及其他類型。 2023年，開角型青光眼佔了最大的市場。

按配銷通路分類，亞太地區青光眼治療市場分為醫院藥房、零售藥房和線上藥房。 2023年，醫院藥局佔了最大的市場佔有率。

按國家/地區分類，亞太地區青光眼治療市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2023年，中國佔據亞太地區青光眼治療市場的主導地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是亞太地區青光眼治療市場領先的公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：亞太青光眼治療市場－關鍵市場動態

  • 青光眼治療市場－關鍵市場動態
  • 市場促進因素
    • 青光眼發生率不斷上升
    • 產品發布、合作和收購的數量不斷增加
  • 市場限制
    • 藥物治療方案依從性問題
  • 市場機會
    • 穿戴式科技的發展
  • 未來趨勢
    • 新型藥物輸送方法的開發
  • 促進因素和限制因素的影響：

第5章：青光眼治療市場－亞太地區分析

  • 2021-2031年青光眼治療市場收入
  • 青光眼治療市場預測分析

第6章：亞太地區青光眼治療市場分析－依藥物類別

  • BETA受體阻斷劑
  • α腎上腺素激動劑
  • 前列腺素類似物
  • 碳酸酐酶抑制劑
  • 聯合用藥
  • 其他

第7章：亞太地區青光眼治療市場分析－按適應症

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第8章：亞太地區青光眼治療市場分析－按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：亞太青光眼治療市場—國家分析

    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太地區其他地區

第 10 章：青光眼治療市場-產業格局

  • 青光眼治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 11 章：公司簡介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 12 章：附錄

Product Code: BMIRE00031612

The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.

Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

Asia Pacific Glaucoma Therapeutics Market Overview

The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.

A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.

Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Glaucoma Therapeutics Market Segmentation

The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Asia Pacific Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Asia Pacific Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Asia Pacific Glaucoma Therapeutics Market Overview
    • 9.1.1 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Asia Pacific Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Asia Pacific Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market